Logo
Home
Company ProfileBoards & StaffsMemberships & PartnersAcademy of JournalismCareersBlog(EN)Contact Us
Our JournalsInstruction for AuthorsBrieflands PoliciesPublish My ResearchJournal Management SystemArticle Processing ChargesOpen Peer ReviewPublishing Services
Publish My Book

International Journal of Endocrinology and Metabolism

Research Institute for Endocrine Sciences

Home
Current IssueAll IssuesIn PressSearch
Instructions
Journal InformationBoards and CommitteesIndexing and Listing SourcesJournal MetricsOpen Peer Review (OPR)Publication Ethics and Malpractice StatementReviewer and AE Registration FormSupportContact Us
APC
Authors GuideSubmit Manuscript

Crossref

1. Risk of recurrence at the time of withdrawal of short- or long-term methimazole therapy in patients with Graves’ hyperthyroidism: a randomized trial and a risk-scoring model

- Fereidoun Azizi

- Atieh Amouzegar

- Davood Khalili

- Hengameh Abdi

- Maryam Tohidi

- Mehdi Hedayati

- Leila Cheraghi

- Yadollah Mehrabi

- Miralireza Takyar

2. Approach to the Patient Considering Long-term Antithyroid Drug Therapy for Graves’ Disease

- Fereidoun Azizi

- Ladan Mehran

- Hengameh Abdi

- Atieh Amouzegar

3. A Predictive Model for Graves’ Disease Recurrence After Antithyroid Drug Therapy: A Retrospective Multicenter Cohort Study

- Omar El Kawkgi

- David Toro-Tobon

- Freddy J.K. Toloza

- Sebastian Vallejo

- Cristian Soto Jacome

- Ivan N. Ayala

- Bryan A. Vallejo

- Camila Wenczenovicz

- Olivia Tzeng

- Horace J. Spencer

- Jeff D. Thostenson

- Dingfeng Li

- Jacob Kohlenberg

- Eddy Lincango

- Sneha Mohan

- Jessica Castellanos-Diaz

- Spyridoula Maraka

- Naykky Singh Ospina

- Juan P. Brito

4. Long-Term Follow-up of Graves Orbitopathy After Treatment With Short- or Long-Term Methimazole or Radioactive Iodine

- Fereidoun Azizi

- Hengameh Abdi

- Ladan Mehran

- Petros Perros

- Safdar Masoumi

- Atieh Amouzegar

5. Iodide-sensitive Graves’ hyperthyroidism and the strategy for resistant or escaped patients during potassium iodide treatment

- Ken Okamura

- Kaori Sato

- Megumi Fujikawa

- Sachiko Bandai

- Hiroshi Ikenoue

- Takanari Kitazono

6. The Early Changes in Thyroid-Stimulating Immunoglobulin Bioassay over Anti-Thyroid Drug Treatment Could Predict Prognosis of Graves’ Disease

- Jin Yu

- Han-Sang Baek

- Chaiho Jeong

- Kwanhoon Jo

- Jeongmin Lee

- Jeonghoon Ha

- Min Hee Kim

- Jungmin Lee

- Dong-Jun Lim

7. Biomarker Test Characteristics and Their Relationship to Healthcare Practices in Iraqi Patients Receiving Hyperthyroidism Treatment

- Mohammed H. Dawood

- Muntadher H. Dawood

- Mohammed Al-Nussairawi

- Mahmoud Gharbavi

8. Sustained Euthyroidism during Thionamide Antithyroid Drug Treatment: Comparison of Short- and Long-term Methimazole Therapy

- Navid Saadat

- Safdar Masoumi

- Mohammad Karim Shahrzad

- Fereidoun Azizi

9. Long-term thionamide antithyroid treatment of Graves' disease

- Fereidoun Azizi

- Hengameh Abdi

- Atieh Amouzegar

- Ali Siamak Habibi Moeini

10. A New Perspective in the Management of Graves’ Hyperthyroidism

- Fereidoun Azizi

11. A Clinical Debate: What Is the Therapeutic Choice for Recurrent Graves’ Hyperthyroidism?

- Hengameh Abdi

- Seyed Rasoul Zakavi

- Fereidoun Azizi

12. Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves’ disease: a systematic scoping review

- F. Azizi

- H. Abdi

- L. Mehran

- A. Amouzegar

13. Control of Graves’ hyperthyroidism with very long-term methimazole treatment: a clinical trial

- Fereidoun Azizi

- Hengameh Abdi

- Atieh Amouzegar